Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.41 |
| ▸ | FLT3 | P36888 | 3/20 | 0.39 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.37 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2952596 | 0.88 | PPARG (0.43) | HDAC6PPARGHSD17B13EPHX2MMP13 | |
| SCHEMBL1684135 | 0.88 | PPARG (0.43) | HDAC6PPARGHDAC1FLT3HSD17B13 | |
| SCHEMBL2948409 | 0.86 | PPARG (0.44) | HDAC6PPARGHSD17B13EPHX2MMP13 | |
| SCHEMBL2948098 | 0.85 | PPARG (0.41) | HDAC6PPARGHSD17B13EPHX2MMP13 | |
| SCHEMBL2945762 | 0.83 | PPARG (0.51) | HDAC6PPARGHDAC1MMP13HDAC8 | |
| SCHEMBL2948441 | 0.83 | PPARG (0.39) | HDAC6PPARGHSD17B13EPHX2MMP13 | |
| SCHEMBL4805639 | 0.80 | HDAC1 (0.52) | HDAC6HDAC1FLT3MMP13IDO1 | |
| SCHEMBL1684141 | 0.77 | HDAC6 (0.53) | HDAC6PPARGHDAC1FLT3MMP13 | |
| SCHEMBL2943380 | 0.72 | MAOB (0.40) | HDAC6HDAC1HDAC8MAOBKDR | |
| SCHEMBL1608357 | 0.72 | PPARG (0.57) | HDAC6PPARGHDAC1FLT3HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | claimed |
| EP-1756103-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | claimed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | claimed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | claimed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| US-7468375-B2 | Inhibitors of the HIV integrase enzyme | PFIZER INC. (US) | 2008-12-23 | — | — | US | disclosed |
| EP-1756103-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | Pfizer, Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | AGOURON PHARMACEUTICALS, INC | 2005-12-15 | — | — | US | disclosed |
| WO-2005103003-A2 | PYRROLOPYRIDINE DERIVATIVES AND THEIR USE AS HIV-INTEGRASE INHIBITORS | PFIZER INC. (US) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277662-A1 | Inhibitors of the HIV integrase enzyme | IMPDH1, INTS9, TYMP | HDAC6 1926/4885PPARG 4290/4885HDAC1 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.